_Interventions for Tobacco Dependence对烟草依赖的心理干预课件.ppt

Disclosure Statement I have received research support (but no consulting or speaking fees) from the following companies that market smoking cessation medications: Learning Objectives Psychiatric morbidity and cessation in two case studies Influence of psychiatric morbidity on smoking cessation Evidence-based cessation treatment for smokers with psychiatric disorders Case Studies Case Studies Case Studies: Smoking History Case Studies * GIM Primary Care Conference Presentation October 25, 2006 University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention Stevens S. Smith, Ph.D. Assistant Professor / Licensed Psychologist Department of Medicine University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention Psychiatric Morbidity and Smoking Cessation SmithKline Beecham GlaxoSmithKline Elan Corporation, plc Adj Disorder w/Anxiety, Tobacco Use Disorder Dysthymia, Tobacco Use Disorder Psychiatric Diagnosis Never married; in 7-yr relationship Never married; not in relationship currently Marital Status Autism Therapist Social Worker Occupation Kariva Aspirin, Bupropion, XL, Desloratadine, Enalapril, Vytorin, Glyburide, Metformin, Levothyroxine, Rosigliatazone Medications None DM Type II, Hypothyroidism, Hyperlipidemia, Hypertension, Atheroscler. Heart Dis. General Medical Conditions 25 y.o., White, Female 60 y.o., White, Female Age, Race, Sex Patient B Patient A 1.40 3.71 (119 in Sept 2005) TSH Tot Chol=232, Triglyc=96, HDL=67, LDL=146 Tot Chol=155, Triglyc=122, HDL=57, LDL=74 Lipids 126/86 130/70 BP Adj Disorder w/Anxiety, Tobacco Use Disorder Dysthymia, Tobacco Use Disorder Psychiatric Diagnosis Exercise 30 min 3x/wk, Weight Watchers No exercise, no special diet Exercise / Diet 159 lbs, 64”, BMI=27.3 (181 lbs, 64”, BMI=31.1) 151 lbs, 61”, BMI=28.5 (no signif change in years) Weight, Ht., BMI None Hx of Alcoholism; no alc for 20+ years Other Hx N/A 7.8% (10.2% in Sept 200